PRESS RELEASES

All Releases
Mar 19, 2018
AUSTIN, Texas , March 19, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a drug development company, announced today that the U.S. Food and Drug Administration ( FDA ) will hold an Advisory Committee Meeting to discuss the New Drug Application (NDA) for REMOXY ER (extended-release
Mar 01, 2018
AUSTIN, Texas , March 01, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today that the U.S. Food and Drug Administration ( FDA ) has determined that a New Drug Application (NDA) for REMOXY ER, the Company’s lead drug candidate, is sufficiently complete to permit a
Feb 13, 2018
AUSTIN, Texas , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today the resubmission to the U.S. Food and Drug Administration ( FDA ) of a New Drug Application (NDA) for REMOXY ® ER, its lead drug candidate.  The Company expects a six-month review cycle by FDA .
Feb 05, 2018
– 2018 Focus will be on REMOXY, Fiscal Discipline and Advancing Pipeline – AUSTIN, Texas , Feb. 05, 2018 (GLOBE NEWSWIRE) --   Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for the year ended December 31 , 2017.  Net loss in 2017 was $11.9 million , or $1.82 per share,
Jan 09, 2018
- Study Meets Primary Endpoint (p - - REMOXY NDA Remains On-Track for Resubmission in Q1 2018 - AUSTIN, Texas, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today announced positive results from a human abuse potential study of its late-stage drug candidate, REMOXY.  Study
Nov 01, 2017
AUSTIN, Texas, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for the third quarter ended September 30, 2017.  Net loss for the third quarter of 2017 was $2.6 million, or $0.40 per share, respectively, compared to a net loss for the same